Product
PD-1/PD-L1 inhibitor
Aliases
PD-1/PD-L1 antibody
5 clinical trials
4 indications
Indication
Advanced Solid TumorIndication
Refractory TumorIndication
Non-Small Cell Lung Cancer Stage IVIndication
lung cancerClinical trial
A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor (Endo) in Combination With Bragg Treatment for Advanced Refractory Non-small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
A Multicenter, Randomized Controlled Clinical Trial of Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line ImmunotherapyStatus: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Preliminary Study on the Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung CancerStatus: Recruiting, Estimated PCD: 2025-08-07
Clinical trial
Treatment of Advanced Refractory Solid Tumors Based on Precise Thymalfasin-regulated PRaG Mode: an Open-label, Prospective, Multicenter Study (PRaG 5.0 Study)Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid TumorsStatus: Completed, Estimated PCD: 2022-10-31